17 January 2013
Despite the apparent consensus opinion at JPM that
innovative new start-ups are continuing to attract capital, I wonder if in
reality the venture funding, particularly from big-pharma CVCs, is mostly
channeled into development/ acquisition of potential clinical candidates - THIS
anomaly of an 'uncharacteristic aversion of domain biggies themselves towards
investing into early innovation that'd feed their own pipelines' is WHAT I feel
is the primary reason for a strong bias in the LP universe against investment
into Life Sciences......